Rapport Therapeutics, Inc. Common Stock (RAPP) — Cash Flow-to-Debt Ratio
Rapport Therapeutics, Inc. Common Stock (RAPP) has a Cash Flow-to-Debt Ratio of -0.50x as of March 2026, meaning its operating cash flow of $-13.06 Million could theoretically repay -1% of its total liabilities ($26.09 Million) in one year. See working capital position of Rapport Therapeutics, Inc. Common Stock to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Rapport Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for Rapport Therapeutics, Inc. Common Stock across 4 annual periods. Also explore RAPP net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Rapport Therapeutics, Inc. Common Stock (2022–2025)
Year-by-year debt coverage analysis for Rapport Therapeutics, Inc. Common Stock. For market capitalisation and broader financial context, see market value of Rapport Therapeutics, Inc. Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.15x | $-87.47 Million | $27.78 Million | ▲ +53.8% |
| 2024 | -6.82x | $-64.83 Million | $9.51 Million | ▼ -4442.7% |
| 2023 | -0.15x | $-27.18 Million | $181.06 Million | ▲ +44.0% |
| 2022 | -0.27x | $-3.24 Million | $12.10 Million | — |